ENTRADA THERAPEUTICS INC (TRDA) Forecast, Price Target & Analyst Ratings

NASDAQ:TRDA • US29384C1080

Current stock price

14.5 USD
+1 (+7.41%)
At close:
14.5931 USD
+0.09 (+0.64%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ENTRADA THERAPEUTICS INC (TRDA).

Forecast Snapshot

Consensus Price Target

Price Target
$21.83
+ 50.54% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 7, 2026
Period
Q1 / 2026
EPS Estimate
-$1.06
Revenue Estimate
1.421M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
86.15%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$21.83
Upside
+ 50.54%
From current price of $14.50 to mean target of $21.83, Based on 13 analyst forecasts
Low
$19.19
Median
$20.40
High
$26.25

Price Target Revisions

1 Month
7.00%
3 Months
29.70%

Price Target Summary

13 Wall Street analysts provided a forecast for the next 12 months for TRDA. The average price target is 21.83 USD. This implies a price increase of 50.54% is expected in the next year compared to the current price of 14.5.
The average price target has been revised upward by 29.7% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

TRDA Current Analyst RatingTRDA Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6

Analyst Ratings History

TRDA Historical Analyst RatingsTRDA Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8 10

Analyst Ratings Consensus

ChartMill Buy Consensus
86.15%
TRDA was analyzed by 13 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about TRDA.
In the previous month the buy percentage consensus was at a similar level.
TRDA was analyzed by 13 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-04-06OppenheimerMaintains Outperform -> Outperform
2026-02-18HC Wainwright & Co.Reiterate Buy -> Buy
2026-02-11GuggenheimInitiate Buy
2025-05-20HC Wainwright & Co.Reiterate Buy -> Buy
2025-03-31HC Wainwright & Co.Reiterate Buy -> Buy
2025-02-25HC Wainwright & Co.Reiterate Buy -> Buy
2025-02-04HC Wainwright & Co.Reiterate Buy -> Buy
2024-12-05Roth MKMInitiate Buy
2024-11-06OppenheimerMaintains Outperform -> Outperform
2024-11-06HC Wainwright & Co.Maintains Buy -> Buy
2024-08-26OppenheimerReiterate Outperform -> Outperform
2024-08-14HC Wainwright & Co.Reiterate Buy -> Buy
2024-06-25HC Wainwright & Co.Maintains Buy -> Buy
2024-03-18HC Wainwright & Co.Reiterate Buy -> Buy
2024-01-05OppenheimerInitiate Outperform
2023-11-27HC Wainwright & Co.Maintains Buy -> Buy
2023-09-22HC Wainwright & Co.Reiterate Buy -> Buy
2023-08-09HC Wainwright & Co.Reiterate Buy -> Buy
2023-08-02HC Wainwright & Co.Reiterate Buy -> Buy
2023-05-24HC Wainwright & Co.Reiterate Buy -> Buy
2023-04-03HC Wainwright & Co.Initiate Buy
2022-11-08Goldman SachsMaintains Neutral
2022-08-16Goldman SachsMaintains Neutral
2022-05-24Goldman SachsMaintains Neutral
2021-11-24Evercore ISI GroupInitiate Outperform

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 7, 2026
Period
Q1 / 2026
EPS Estimate
-$1.06
Revenue Estimate
1.421M
Revenue Q2Q
-93.09%
EPS Q2Q
-151.78%
Number of Analysts
10

Next Earnings Revisions

Revenue (1 Month)
-16.66%
Revenue (3 Months)
-84.54%
EPS (1 Month)
-1.73%
EPS (3 Months)
-3.74%

Next Earnings Summary

TRDA is expected to report earnings on 5/7/2026. The consensus EPS estimate for the next earnings is -1.06 USD and the consensus revenue estimate is 1.42M USD.
The next earnings revenue estimate has been revised downward by 84.54% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
TRDA revenue by date.TRDA revenue by date.
129.013M210.782M
63.38%		25.421M
-87.94%		35.582M
39.97%		53.657M
50.80%		68.621M
27.89%		85.368M
24.41%		218.88M
156.40%		309.39M
41.35%		419.64M
35.63%		621.24M
48.04%
EBITDA
YoY % growth
TRDA ebitda by date.TRDA ebitda by date.
-321K
99.66%		50.784M
15,920.56%		-153.802M
-402.86%		-175.754M
-14.27%		-223.909M
-27.40%		-357.974M
-59.87%		N/AN/AN/AN/AN/A
EBIT
YoY % growth
TRDA ebit by date.TRDA ebit by date.
-3.162M
96.75%		47.011M
1,586.75%		-157.898M
-435.87%		-187.751M
-18.91%		-215.058M
-14.54%		-233.59M
-8.62%		-192.304M
17.67%		-105.801M
44.98%		-64.367M
39.16%		-18.689M
70.96%		109.65M
686.70%
Operating Margin
TRDA operating margin by date.TRDA operating margin by date.
-2.45%22.30%-621.13%-527.66%-400.80%-340.41%-225.26%-48.34%-20.80%-4.45%17.65%
EPS
YoY % growth
TRDA eps by date.TRDA eps by date.
-0.26
91.39%		1.91
834.62%		-3.46
-281.15%		-3.99
-15.39%		-3.76
5.80%		-3.56
5.40%		-2.19
38.45%		-1.29
41.31%		-0.98
23.55%		0.41
141.52%		2.25
452.50%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27 Q1 / 28 Q2 / 28 Q3 / 28 Q4 / 28
EPS
Q2Q % growth		-1.06
-151.78%		-1.10
-6.23%		-0.95
9.93%		-0.91
2.82%		-1.06
-0.31%		-1.06
4.29%		-1.03
-8.26%		-1.00
-9.43%		-1.28
-20.19%		-1.22
-15.76%		-1.15
-11.51%		-1.11
-11.22%
Revenue
Q2Q % growth		1.421M
-93.09%		1.421M
-27.13%		10.431M
546.28%		11.281M
768.44%		8.854M
523.08%		9.364M
558.97%		9.874M
-5.34%		10.384M
-7.95%		3.692M
-58.30%		9.71M
3.70%		17.085M
73.03%		24.266M
133.69%
EBITDA
Q2Q % growth		-34.136M
-63.77%		-37.537M
16.34%		-44.833M
-2.26%		-48.305M
-26.75%		N/AN/AN/AN/AN/AN/AN/AN/A
EBIT
Q2Q % growth		-45.843M
-110.39%		-50.441M
-7.67%		-45.786M
2.69%		-45.681M
-8.23%		-51.498M
-12.34%		-52.645M
-4.37%		-53.819M
-17.55%		-55.02M
-20.44%		N/AN/AN/AN/A

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

TRDA Yearly Revenue VS EstimatesTRDA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M
TRDA Yearly EPS VS EstimatesTRDA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 -4 -6 -8

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
-0.93%
EPS Next 5 Year
10.25%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
30.24%
Revenue Next 5 Year
47.77%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
-28.10%
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

ENTRADA THERAPEUTICS INC / TRDA Forecast FAQ

What do analysts expect the price target to be for ENTRADA THERAPEUTICS INC (TRDA)?

13 analysts have analysed TRDA and the average price target is 21.83 USD. This implies a price increase of 50.54% is expected in the next year compared to the current price of 14.5.

What is the next earnings date for TRDA stock?

ENTRADA THERAPEUTICS INC (TRDA) will report earnings on 2026-05-07, before the market open.

What are the consensus estimates for TRDA stock next earnings?

The consensus EPS estimate for the next earnings of ENTRADA THERAPEUTICS INC (TRDA) is -1.06 USD and the consensus revenue estimate is 1.42M USD.

Can you provide the analyst count for ENTRADA THERAPEUTICS INC stock?

The number of analysts covering ENTRADA THERAPEUTICS INC (TRDA) is 13.